Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?

Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?

Key PointsEli Lilly's fourth-quarter revenue rose by 43%, largely a result of its impressive GLP-1 products.Sales from its GLP-1 drugs doubled, and they are key components of the company's business.The stock trades at a high valuation, and the premium may be hard to justify as competition in the GLP-1 space could intensify in the near future.10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been a growth beast over the years, t…